ArticlesCognitive-Behavioral Therapy for Medication-Resistant Schizophrenia: A ReviewRATHOD, SHANAYA, MD, MRCPsych; KINGDON, DAVID, MD; WEIDEN, PETER, MD; TURKINGTON, DOUGLAS, MDAuthor Information RATHOD: Mid Hampshire and Eastleigh TVS Locality, Winchester, UK; KINGDON: University of Southampton, Royal South Hants Hospital, Southampton, UK; WEIDEN: University of Illinois at Chicago; TURKINGTON: University of Newcastle-upon-Tyne, Royal Victoria Infirmary, Newcastle-upon-Tyne, UK Please send correspondence and reprint requests to: Shanaya Rathod, MD, MRCPsych, Associate Medical Director, Mid Hampshire and Eastleigh TVS Locality, Melbury Lodge, Romsey Road, Winchester, SO22 5DG. email@example.com Journal of Psychiatric Practice®: January 2008 - Volume 14 - Issue 1 - p 22-33 doi: 10.1097/01.pra.0000308492.93003.db Buy SDC Metrics Abstract Research meta-analyses have found that cognitive-behavioral therapy (CBT) is beneficial for persistent symptoms of schizophrenia. This review describes and updates the evidence base for this statement. A review of the existing literature (Medline, PsychInfo, and Embase) was carried out according to the guidelines for systematic reviews. Based on the findings of this review, the updated conclusion is that CBT has emerged as an effective adjuvant to antipsychotic medication in the treatment of persistent symptoms of schizophrenia. Studies of the use of CBT in the prodromal phase of psychosis and in combination with family therapy are currently underway. Copyright © 2008 Wolters Kluwer Health, Inc. All rights reserved.